Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Clinical Trials Related to Pembrolizumab
Related studies linked through entity extraction aliases.
A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer
- Status
- RECRUITING
- Phase
- PHASE2
A Study to Assess YH003 in Combination with Pebolizumab and Albumin Paclitaxel Injection in Subjects with Unresectable/metastatic Mucosal Melanoma
- Status
- COMPLETED
- Phase
- PHASE2
Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System
- Status
- WITHDRAWN
- Phase
- PHASE2
A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Pembrolizumab in Muscle-invasive Bladder Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of MK-1088 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-1088-002)
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Intermediate-size IND for Treatment of KRAS G12V-mutant Tumors
- Status
- TEMPORARILY_NOT_AVAILABLE
- Phase
- N/A
Pembrolizumab and Photodynamic Therapy in Previously Treated Metastatic Esophageal Squamous Cell Carcinoma
- Status
- UNKNOWN
- Phase
- PHASE2
Study of Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-stage Small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Neoadjuvant/Adjuvant Pembrolizumab Plus Chemotherapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of ASP3082 in Adults With Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers
- Status
- COMPLETED
- Phase
- PHASE2
A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Pembrolizumab in Small Cell Carcinoma of Ovary - Hypercalcemic Type Patient
- Status
- COMPLETED
- Phase
- NA
Pembrolizumab Plus Olaparib in LA-HNSCC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
ERC1671 to Treat Malignant Gliomas When Given in Combination With GM-CSF, Cyclophosphamide, Bevacizumab and Pembrolizumab
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2